Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Not yet recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

not_yet_recruiting267%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_2

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

NCT07628062
not_yet_recruitingphase_2

NAI for Sepsis With Persistent Lymphopenia

NCT07578558
withdrawnphase_3

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

NCT07492875

Clinical Trials (3)

Showing 3 of 3 trials
NCT07628062Phase 2

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

Not Yet Recruiting
NCT07578558Phase 2

NAI for Sepsis With Persistent Lymphopenia

Not Yet Recruiting
NCT07492875Phase 3

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3